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The wild-type and mutant derivatives of the integrase protein of feline immunodeficiency virus (FIV) were cloned and
expressed in Escherichia coli. The purified proteins were examined using various model DNA substrates for their catalytic
activities: 3*-end processing, 3*-end joining, and disintegration. The reactions required the presence of either Mn2/ or Mg2/
as a divalent cation. The N-terminal and C-subterminal domains (residues 1–52 and 189–235, respectively) were necessary
for 3*-end processing and joining reactions but not for disintegration. Substitution of asparagine for the highly conserved
aspartic acid at position 118 resulted in a complete loss of all three activities, confirming that the catalytic domain resides
in the central core region (residues 53–188) of the protein. Deletion of the C-terminus (residues 236–281) resulted in a
FIV integrase mutant that had efficient 3*-end processing and disintegration activities but weak 3*-end joining activity, a
finding that has not been reported previously with other retroviral integrases. The result suggests that the C-terminus is
the primary binding site for target DNA. Attachment of a histidine-tag at the N-terminus of the wild-type and deletion
derivatives increased the binding affinity to the DNA substrate, resulting in altered levels of catalytic activities and selection
of integration sites. Similar to other retroviral integrases, certain pairs of mutant derivatives of FIV integrase could comple-
ment each other to restitute 3*-end processing and joining activities, suggesting that formation of functional multimers is
a general feature of proteins in the integrase family. q 1997 Academic Press
INTRODUCTION repair of the gaps between the viral and target DNA,
thereby generating the short direct repeats that flank the
An essential step in the life cycle of retroviruses is provirus.
integration of a double-stranded DNA copy of the viral In vitro studies using model viral DNA substrates
RNA genome into the host cell chromosome (LaFemina showed that purified integrase alone can catalyze the 3*-
et al., 1992; Sakai et al., 1993; Cannon et al., 1994; Shin end processing and 3*-end joining steps of the reaction
et al., 1994; Engelman et al., 1995; Englund et al., 1995). (Craigie et al., 1990; Katz et al., 1990; Bushman and Crai-
Integration requires a viral protein integrase, and DNA gie, 1991; Pahl and Flugel, 1993; Bushman and Wang,
sequences at the ends of the viral long terminal repeats 1994; Katzman and Sudol, 1994; Vink et al., 1994). Integ-
(LTR). Analysis of the integration reaction in vivo and in rase also catalyzes a reversal of the 3*-end joining reac-
vitro has demonstrated that it proceeds in three steps (for tion, termed disintegration (Chow et al., 1992). The pro-
reviews, see Brown, 1990; Goff, 1992; Vink and Plasterk, tein factors involved in 5*-end joining, the last step of the
1993). The first step is 3*-end processing, which involves reaction, remain to be characterized, though they are
the removal of two nucleotides from the 3* end of each generally presumed to be cellular repair enzymes.
strand of linear viral DNA so that the viral 3* ends termi- Mutational analyses of several retroviral integrases
nate with the conserved CA dinucleotide. The second have identified at least three distinct functional domains
step is 3*-end joining (strand transfer), a concerted cleav- (Engelman and Craigie, 1992; Kulkosky et al., 1992; En-
age–ligation reaction during which integrase makes a gelman et al., 1993; van Gent et al., 1993; Jonsson et al.,
staggered cut in the target DNA and ligates the recessed 1996): (i) a HHCC domain in the N-terminus, named for
3* ends of the viral DNA to the 5* ends of the target DNA its zinc finger-like motif HX3 – 7HX23 – 32CX2C, (ii) a DD35E
at the cleavage site. The product of the reaction is a domain located within a protease-resistant core con-
gapped intermediate. The last step is 5*-end joining. The taining the motif DX39 – 58DX35E, and (iii) a C-terminus do-
integration process is completed by removal of the two main that represents the least conserved region among
unpaired nucleotides at the 5* ends of the viral DNA and retroviral integrases. The HHCC domain is critical for
forming a stable complex with viral DNA, and the domain
may be involved in multimerization of integrase (Ellison1 Present address: School of Pharmaceutical Sciences, Kitasato Uni-
and Brown, 1994; Ellison et al., 1995). The DD35E domainversity, Tokyo 108, Japan.
is the putative catalytic site (Engelman and Craigie, 1992;2 To whom correspondence and reprint requests should be ad-
dressed. Fax: (310) 825-6267. E-mail: schow@pharm.medsch.ucla.edu. Kulkosky et al., 1992; Bushman et al., 1993; Leavitt et al.,
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1993) and is a highly conserved motif found in retrovi- polymerase I were from United States Biochemical. A 12-
residue peptide (synthetic His-tag; sequence: MHHHHH-ruses and retrovirus-like elements (Polard and Chandler,
1995). The C-terminal domain is capable of binding DNA HHIVPR) was obtained from Research Genetics, Inc. De-
oxyribonucleotides were purchased from Pharmacianonspecifically and is believed to contain the site for
binding target DNA (Kahn et al., 1991; Woerner et al., LKB. [g-32P]ATP and [a-32P]dCTP were obtained from Am-
ersham at a specific activity of 6,000 Ci/mmol. Oligonu-1992; Vink et al., 1993; Engelman et al., 1994; Puras
Lutzke et al., 1994). cleotides were purchased from Operon Technologies,
Inc., and were purified by electrophoresis through a 15%Feline immunodeficiency virus (FIV) is a lentivirus with
a complex genomic organization resembling that of pri- denaturing polyacrylamide gel before use.
mate lentiviruses, such as HIV (Talbott et al., 1989). Infec-
tion of cats with FIV produces an immunodeficiency syn- Cloning and expression of wild-type and mutant FIV
drome that is remarkably similar to that caused by HIV integrases
in humans (Pedersen et al., 1987). We are interested in
using FIV as a model system for studying lentivirus infec- Wild-type and derivatives of FIV integrase were pre-
pared by constructing plasmids encoding the wild-typetion and mechanism of integration. Availability of an ani-
mal model will allow experiments to be carried out in and mutant proteins. The wild-type and mutant FIV integ-
rase genes were amplified by polymerase chain reactionvivo, and the results obtained can be used for comparing
and corroborating observations made in vitro. The amino (PCR) using the molecular FIV clone 34TF10 (kindly pro-
vided by T. Phillips at the Scripps Research Institute) asacid sequence of FIV integrase is 37% identical to that
of HIV-1 integrase (Talbott et al., 1989). FIV integrase has the template (Talbott et al., 1989). The primers for the
N-terminus of the full-length (WT) and the N-terminuspreviously been purified as a fusion protein with maltose
binding protein, and the fusion protein has 3*-end pro- truncated (IN53-281; deletion of amino acid residues 1–
52) integrases were 5*-CCAGTGCATATGTCCTCTTGG-cessing, 3*-end joining, and disintegration activities (Vink
et al., 1994). However, the functional domains of FIV in- GTTGACAGA-3* and 5*-CCAGTGCATATGGGAGGACAA-
TTGAAAATA-3*, respectively. The N-terminus primerstegrase have not been analyzed. Also, it is not known
whether the activities of FIV integrase have been altered contain an NdeI site (underlined). The primers for the C
terminus of the full-length and the C-terminus truncatedin the presence of the maltose-binding protein. This is
important because in vitro activities of truncated integ- integrases, IN1-188 (deletion of amino acid residues
189–281) and IN1-235 (deletion of amino acid residuesrases of Rous sarcoma virus (RSV) and HIV-1 are greatly
influenced by fusing integrase with various short pep- 236–281), were 5*-GGTCACGGATCCTTACTCATCCCC-
TTCAGG-3*, 5*-GGTCCTGGATCCTTATTTAAAATTGAG-tides (Bushman and Wang, 1994; Hickman et al., 1994).
In this study, the functional domains of FIV integrase ACTA-3*, and 5*-GGTCCTGGATCCCTATTTCTTATCTTT-
TTGATC-3*, respectively. The C-terminus primers containwere mapped by analyzing the in vitro activities of the
wild-type protein and various substitution and deletion a BamHI site (underlined) and a stop codon (italicized).
The N-terminus primer for the mutant protein IN53-235,mutants. Presence of a histidine-tag at the N-terminus
of integrase, which increased the binding affinity of the which corresponds to the core domain of FIV integrase,
was identical to that of IN53-281, while the C-terminusprotein to the DNA substrate, affects both the activity of
the protein and the selection of host target sites. Comple- primer was identical to that of IN1-235. The PCR products
were digested with NdeI and BamHI, purified by agarosementation experiments showed that FIV integrase func-
tions as a multimer, and different functions can be pro- gel electrophoresis and ligated to pT7-7(His) plasmid
DNA, previously cut with NdeI and BamHI. The plasmidvided by discrete domains on different subunits. Interest-
ingly, the C-terminal domain of FIV integrase is not pT7-7(His) is derived from pT7-7, a T7 RNA polymerase-
promoter system (Tabor and Richardson, 1985), and itessential for 3*-end processing and joining activities, a
finding that has not been reported previously with other contains an ATG initiation codon and seven consecutive
histidine codons upstream of the unique NdeI site ofretroviral integrases.
pT7-7 (Goulaouic and Chow, 1996). The resulting plas-
mids were cleaved with NdeI and a double-strandedMATERIALS AND METHODS
oligonucleotide (5*-TATCGTTCCGCGTGGATC-3* and 5*-
Enzymes and reagents
TAGATCCACGCGGAACGA-3*) encoding a thrombin cleav-
age site was inserted. These manipulations resulted in theHIV-1 integrase was purified as described previously
(Goulaouic and Chow, 1996). T4 polynucleotide kinase, attachment of 15 amino acid residues (sequence: MHH-
HHHHHIVPRGSM) at the N-terminus of the integrase cod-T4 DNA ligase, and restriction endonucleases were pur-
chased from New England Biolabs; AmpliTaq DNA poly- ing sequence.
The DNA encoding a mutant FIV integrase D118N,merase was from Perkin–Elmer–Cetus; modified T7
DNA polymerase (Sequenase version 2.0) and exo- which has an asparagine substituting for the highly con-
served aspartic acid at position 118, was obtained bynuclease-free Klenow fragment of Escherichia coli DNA
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performing two sequential PCR amplifications. The tem- tained 2 ml of SP-Sepharose HP (Pharmacia). After sam-
ple loading, the column was washed with 5 ml of bufferplate for both PCRs was pFIV34TF10 plasmid DNA. The
3*-primer for the first PCR contains the desired mutation D plus 60 mM NaCl, and the protein was eluted in a total
volume of 40 ml with a linear gradient from buffer D plus(5*-TTTGGTCCATTATTTGTTTGTAATTC-3*; the bold let-
ter denotes the mutation), and the 5*-primer was identical 60 mM NaCl to buffer D plus 700 mM NaCl. The fractions
containing the desired protein were pooled, concen-to that described earlier for the N-terminus of the WT
integrase. The PCR product was purified by a QIAquick trated on a Centricon-10 column (Amicon), and dialyzed
against storage buffer (20 mM HEPES, pH 7.5, 0.1 mMspin column (QIAGEN) and was used as the 5*-primer
in a second PCR, while the C-terminus primer described EDTA, 0.3 M NaCl, 20% glycerol, 10 mM DTT, and 10 mM
CHAPS). Protein concentrations were determined by theearlier for the WT integrase was used as the 3*-primer.
The PCR product was then digested with NdeI and Bradford method (Bio-Rad) using bovine serum albumin
(BSA) as a standard.BamHI, purified, and cloned into pT7-7(His) plasmid DNA
as described earlier for the WT and truncated integrases. To obtain protein with the attached His-tag, the throm-
bin-digestion step was omitted, and the protein obtainedThe sequences of all the PCR-amplified DNA frag-
ments were verified by restriction analysis and the di- after the Ni-NTA column was applied to the SP-Sepha-
rose column and eluted as described earlier. Preliminarydeoxynucleotide chain termination method. Sequencing
reactions were carried out with a modified T7 DNA poly- experiments showed that, after the Ni-NTA column and
before the SP-Sepharose column, incubation of the sam-merase according to manufacturer’s specification.
The DNA constructs were transformed into E. coli BL21 ple at 307 for 4 hr did not affect the activity of the resulting
protein.(DE3). The cells were grown at 357 in 4 liters of LB me-
dium containing 50 mg of ampicillin per milliliter. At an
optical density of 0.8, isopropyl-1-thio-b-D-galactopyra- Assays for integrase activity
noside was added to 0.3 mM for expression induction,
and the culture was grown for an additional 5 hr. After The 3*-end processing, 3*-end joining, and disintegra-
tion activities of the fusion proteins were assayed asharvesting, the cell pellet was frozen at 0807.
previously described (Chow et al., 1992; Vincent et al.,
1993). The following oligonucleotides (Operon Technolo-Purification of wild-type and mutant FIV integrase
gies, Inc.) were used as DNA substrates: F-U5V1, 5*-
CCGGGCCGAGAACTTCGCAGT (bold letters denote theThe frozen bacterial pellet was resuspended in 100 ml
of a buffer containing 20 mM N-2-hydroxyethylpiperazine- invariant CA dinucleotide); F-U5V1-2, 5*-CCGGGCCGA-
GAACTTCGCA; F-U5V2; 5*-ACTGCGAAGTTCTCGGCC-N*-2-ethanesulfonic acid [HEPES, pH 7.5], 0.2 mM EDTA,
1 M NaCl, 10% glycerol, 5 mM 2-mercaptoethanol, 1 mM CGG; F-V1/T2, 5*-CCGGGCCGAGAACTTCGCAGGCTG-
CAGGTCGAC; T1, 5*-CAGCAACGCAAGCTTG-3*; T3, 5*-phenylmethylsulfonyl fluoride (PMSF), and 0.5% Nonidet
P-40. The cell suspension was sonicated and centrifuged GTCGACCTGCAGCCCAAGCTTGCGTTGCTG-3*; H-U5V1,
5*-ATGTGGAAAATCTCTAGCAGT; H-U5V2; 5*-ACTGCTAGA-at 100,000 g for 1 hr at 47. The supernatant, after dialysis
against buffer A (20 mM HEPES, pH 7.5, 1 M NaCl, 10% GATTTTCCACAT; M-U5V1, 5*-ACCTACAGGTGGGGTCTT-
TCATT; M-U5V2; 5*-AATGAAAGACCCCACCTGTAGGT. Theglycerol, 5 mM 2-mercaptoethanol, 0.1% Nonidet P-40),
was gently shaken on ice for 2 hr with 2.5 ml of Ni2/- oligonucleotides were purified by electrophoresis through a
15% denaturing polyacrylamide gel. Oligonucleotides F-nitrilotriacetic acid agarose (Ni-NTA resin; QIAGEN). The
resin was washed five times with 10 ml of buffer A plus U5V1, F-U5V1-2, H-U5V1, M-U5V1, and T1 were labeled
at the 5* end with [g-32P]ATP by using T4 polynucleotide50 mM imidazole and then packed into a column. The
protein was eluted in a total volume of 20 or 30 ml with kinase.
The substrate used to assay the 3*-end processinga linear gradient from buffer A plus 50 mM imidazole to
buffer A plus 500 mM imidazole. The fractions containing and 3*-end joining activities of wild-type and mutant FIV
integrases was a double-stranded oligonucleotide con-the protein were pooled and dialyzed against buffer C
(20 mM HEPES, pH 7.5, 0.1 mM EDTA, 0.5 M NaCl, 20% taining sequences derived from the U5 end of the FIV
LTR terminus. The substrate was prepared by annealingglycerol, 1 mM dithiothreitol (DTT), and 10 mM 3-[(3-chol-
amidopropyl)-dimethyl-ammonio]-1-propanesulfonate the labeled F-U5V1 strand with its complementary oligo-
nucleotide F-U5V2. The HIV-1 U5 and MLV U5 substrates(CHAPS)).
To remove the His-tag, the isolated protein was incu- were prepared by annealing the labeled H-U5V1 strand
with H-U5V2 and the labeled M-U5V1 strand with M-bated in buffer C with bovine thrombin (Sigma; 25 Na-
tional Institutes of Health units/mg integrase) at 307 for U5V2, respectively. To assay only the 3*-end joining activ-
ity, a substrate that resembles the viral U5 end after 3*-4 hr. The sample was then diluted with 10 vol of buffer
D (20 mM HEPES, pH 7.0, 0.1 mM EDTA, 10% glycerol, end processing was used. The preprocessed substrate
was prepared by annealing the labeled F-U5V1-2 strand10 mM DTT, and 10 mM CHAPS). The cleaved His-tag
was separated from integrase using a column that con- with the F-U5V2 strand. The FIV disintegration substrate
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(Y-oligomer) was prepared by annealing the labeled T1
strand with oligonucleotides T3, F-V1/T2, and F-U5V2,
and purifying the annealed product on a 15% native poly-
acrylamide gel. Typically in a 20-ml vol, 0.1 pmol of the
labeled DNA was incubated with FIV integrase for 60
min at 377 in a reaction buffer containing a final concen-
tration of 20 mM HEPES, pH 7.5, 10 mM MnCl2 , 30 mM
NaCl, 10 mM DTT, 0.01 mM EDTA, 20% glycerol, 1 mM
CHAPS, and 0.05% Nonidet P-40.
The concentrations of integrases used throughout this
paper refer to protomers and not necessarily active en-
zyme molecules. In all assays, the reaction was stopped
by adding a final concentration of 18 mM EDTA, pH 8.0.
The reaction products were mixed with an equal volume
of loading buffer (98% deionized formamide, 10 mM
EDTA, pH 8.0, 0.05% bromophenol blue, 0.05% xylene
cyanol), and heated at 907 for 3 min before analysis by
electrophoresis on 15% polyacrylamide gels with 7 M
urea in Tris–taurine–EDTA buffer. Alternatively, the reac-
tion products were precipitated and washed with ethanol,
and resuspended in formamide loading buffer before
analysis by electrophoresis on 15% denaturing polyacryl-
amide gels in Tris–borate–EDTA buffer. Quantitation of
the products was carried out with a Molecular Dynamics
PhosphorImager.
Nitrocellulose filter binding assay
A filter binding assay was used to measure the binding
affinity of FIV integrase and its mutant derivatives to DNA
(Chiu et al., 1990). Nitrocellulose filters (Schleicher &
FIG. 1. (A) Primary structure of FIV integrase and its mutant derivatives.Schuell, type BA85; 0.45 mm) were treated with 0.4 M
Wild-type FIV integrase (WT) has 281 amino acids. The amino acids thatKOH for 5 min and then rinsed extensively with distilled
made up the highly conserved zinc finger (HHCC) and catalytic (DD35E)water. The filters were soaked in 1 ml of prewash buffer
motifs are denoted by vertical lines. The numbers above the lines are the
containing 20 mM HEPES, pH 7.5, 10 mM MnCl2 10 mM positions and the letters below the lines are the identities of the amino
NaCl, and 100 mg/ml sonicated salmon sperm DNA. A acids. Deletion mutants are represented schematically below the WT. The
numbers by each deletion mutant refer to the amino acid residues of the20-ml aliquot of the sample containing various concentra-
WT that are retained in the mutant. For the point mutant D118N, an asterisktions of [32P]DNA and 250 or 750 nM integrase was
indicates the substitution of asparagine for the highly conserved asparticadded into 1 ml of prewash buffer and filtered. The filters
acid at position 118. All proteins were expressed as a fusion to a His-
were washed twice with 4 ml of wash buffer (20 mM tag. Not included in the figure are the three amino acids (GSM) that
HEPES, pH 7.5, 10 mM MnCl2 , 10 mM NaCl). Filters were remained at the N-terminus after removal of the His-tag by thrombin
cleavage. (B) SDS–PAGE of FIV integrase and its mutant derivatives. Thedried and the percentage of DNA bound to the filter was
stacking gel contained 8 M urea and the gel was stained with Coomassiedetermined by liquid scintillation counting.
blue. Lanes 2–6 are aliquots from the purification of the WT integrase.
Lane 2 is the supernatant fraction after centrifugation of the bacterial
RESULTS lysate at 100,000 g. Lane 3 is the sample that passed through the Ni-
NTA resin. Lane 4 is the pooled fraction eluting off the Ni-NTA column
Purification of wild-type and mutant FIV integrases with a linear gradient of imidazole (Ni-pool). Lane 5 is the Ni-pool digested
with thrombin. Lane 6 is the pooled fraction after the SP-Sepharose chro-
FIV integrase and its mutant derivatives were ex- matography. Lanes 8–13 are purified WT and its mutant derivatives as
pressed with a short extension at the N-terminus that indicated on the top of the panel. Lanes 1, 7, and 14 contain the molecular
weight standards with the masses (in kilodaltons) indicated on the left ofincludes seven histidine residues (His-tag) and a throm-
the panel.bin cleavage site. The His-tag provides a rapid purifica-
tion by nickel-chelating affinity chromatography (Fig. 1B,
lanes 2–4), and the thrombin cleavage site allows the matography through a SP-Sepharose column (Fig. 1B,
lane 6). The N-terminus of the resulting viral protein con-subsequent removal of the His-tag by cleavage with
thrombin (Fig. 1B, lane 5). The viral protein was purified tains three extra residues: glycine, serine, and methio-
nine. The apparent molecular mass of FIV integrase de-from the His-tag and thrombin by cation exchange chro-
AID VY 8466 / 6a2f$$$$42 03-04-97 01:36:51 vira AP: Virology
5FUNCTIONAL DOMAINS OF FIV INTEGRASE
TABLE 1termined by sodium dodecyl sulfate–polyacrylamide gel
electrophoresis (SDS–PAGE) was approximately 31 kDa, Catalytic Activitiesa of FIV Integrase and Its Mutant Derivatives
consistent with that predicted by the amino acid se-
Integrase 3*-end 3*-endquence (Talbott et al., 1989).
derivative processing joining DisintegrationAt the final stage, the purities of wild-type and mutant
integrases ranged from 80 to 90%, with a majority of the
WT //// //// ////
contaminants consisting of faster-migrating polypeptides IN53-281 0 0 ////
(Fig. 1B, lanes 8–13). These contaminants were presum- IN1-235 // { //
IN1-188 0 0 {ably premature termination or break-down products
IN53-235 0 0 /since they reacted with integrase-specific antisera on a
D118N 0 0 0Western immunoblot (data not shown). Several proteins,
such as IN53-281 and IN53-235 (Fig. 1B, lanes 9 and 12), a Results are expressed as the percentage of the activity of wild-
appeared as a smear on a SDS–PAGE gel. The smear type FIV integrase (WT). Under standard reaction conditions, the prod-
uct yields of 3*-end processing, 3*-end joining, and disintegration ofwas due to protein aggregation, even in the presence of
WT integrase were 75, 15, and 70%, respectively. Each / corresponds0.1% SDS. The protein appeared as a discrete band when
to 25% of wild-type activity; {, 10% of wild-type activity; 0, no activity.analyzed on a SDS–PAGE gel that contained 8 M urea
A double-strand oligonucleotide (F-U5V1/F-U5V2) was used for 3*-end
(data not shown). processing, and a preprocessed oligonucleotide (F-U5V1-2/F-U5V2)
was used for 3*-end joining. Reactions were conducted with 5 nM U5
Catalytic activities of wild-type FIV integrase DNA and 250 nM wild-type FIV integrase or its mutant derivatives in the
presence of 30 mM NaCl. For IN1-235, the reactions were conducted in
Under optimal reaction conditions (see Materials and the presence of 10 mM NaCl. At 30 mM NaCl, the 3*-end processing
activity was 10% of that of WT, and no 3*-end joining activity wasMethods), FIV integrase efficiently mediated 3*-end pro-
detectable. For other deletion derivatives, the levels of activities werecessing, 3*-end joining, and disintegration (Fig. 2 and
the same at 10 or 30 mM NaCl.Table 1). All three reactions required the presence of a
divalent cation, and an optimal yield was obtained with
10 mM MnCl2 or 3 mM MgCl2 . Reactions carried out in
MgCl2 were stimulated by the addition of 15% DMSO
(data not shown). When comparing with MnCl2 , reactions
conducted in the presence of MgCl2 were 3- to 10-fold
poorer but had substantially less nonspecific nuclease
activity (Fig. 2A).
FIV integrase appeared to have a relaxed sequence
requirement for end-processing and joining since the
protein could use both HIV-1 and MLV U5 DNA as sub-
strates (Fig. 2B), which differ considerably in sequences
(Brown, 1990). Similarly, HIV-1 integrase could use FIV
U5 DNA as a substrate (Fig. 2C). Importantly, the banding
patterns of the 3*-end joining products, which reflect the
frequency of use and positions of the joining site, were
different between the two integrases (Fig. 2C).
The kinetics of 3*-end processing activity were deter-
mined under the optimal reaction condition (Fig. 3). The
apparent Km for the double-stranded 21-bp oligonucleo-
FIG. 2. In vitro activities of FIV integrase. (A) Requirement of a divalent tide substrate was 42 nM. In the presence of 125 nM
cation. Five nanomolar of the singly 5*-end labeled, blunt-ended FIV of FIV integrase and 10-fold molar excess of the DNA
U5 DNA substrate was incubated with various concentrations of FIV
substrate, less than 3% of the substrate was convertedintegrase in the presence of 10 mM MnCl2 (lanes 1–4) or 3 mM MgCl2
into product after a prolonged incubation (data notand 15% DMSO (lanes 5–8). In the presence of MgCl2 , the optimal
product yields of 3*-end processing, 3*-end joining, and disintegration shown). FIV integrase, therefore, similar to MLV integ-
of WT integrase were 8, 3, and 25%, respectively. (B) Use of other U5 rase, failed to turn over in the 3*-end processing reaction
DNA substrates. FIV integrase (250 nM) was incubated with 10 mM (Dotan et al., 1995). Whether or not FIV integrase is capa-
MnCl2 and 5 nM labeled DNA substrate containing sequences derived ble of turning over in the disintegration reaction has notfrom the U5 end of the HIV (lane 9) or MLV (lane 10) LTR terminus. (C)
been determined.Activity of HIV-1 integrase on FIV U5 DNA substrate. The reaction
mixture contains 10 mM MnCl2 , 5 nM of labeled FIV U5 DNA, and 125
(lane 11) or 250 nM (lane 12) HIV-1 integrase. The filled arrowhead Catalytic activities of mutant FIV integrase
indicates the position of the substrate, and the open arrowhead indi-
To deduce the functional domain of integrase, differentcates the position of the 3*-end processing product. The 3*-end joining
(strand transfer) product is marked by s.t.p. derivatives of the wild-type protein were prepared and
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changed when Mg2/ was used as the divalent cation
(data not shown).
HIV-1 or MLV integrase forms functional multimers and
each monomer comprises discrete functional domains
that can complement each other (Engelman et al., 1993;
van Gent et al., 1993; Jonsson et al., 1996). Complementa-
tion analysis of various mutant FIV integrases showed
that both 3*-end processing and 3*-end joining activities
could be restored by mixing IN53-281 with IN1-235, or
by mixing the D118N mutant with either IN53-281, IN1-
235, or the core domain IN53-235 (data not shown). The
results showed that within a mixed functional multimer,
only one protein of the complementation pair requires
an active core domain, and the N- (residues 1–52) and
the C-terminal domain (residues 235–281) can be com-
plementary in trans to the active core. No complementa-
tion was observed between D118N and IN1-188, sug-
gesting that the C-subterminal domain (residues 189–
234) functions in cis to the active core domain (dataFIG. 3. Kinetic parameters of 3*-end processing activity. Reactions
were carried out under standard reaction conditions in the presence not shown). In addition, different mixtures of integrases
of 100 nM FIV integrase and 10 –250 nM of the double-stranded oligo- containing a mutation or deletion in different domains
nucleotide (F-U5V1/F-U5V2) as the DNA substrate. Reaction velocities also could mediate trans-disintegration using a cross-
at various substrate concentrations were determined (data not shown)
bones substrate (data not shown), an assay that requiresand were transformed into a direct linear plot to obtain the Km and Vmax
the juxtaposition of two DNA substrates by integrase(Dowd and Riggs, 1965). v, reaction velocity; [s], substrate concentra-
tion. (Chow and Brown, 1994). The result further supports that
FIV integrase, similar to HIV-1 integrase, functions as a
multimer.
purified (Fig. 1). These include a protein containing a
Effect of a histidine-tag on wild-type and mutantdeletion at the N-terminus (IN53-281), two proteins con-
integrasestaining different deletions at the C-terminus (IN1-188 and
IN1-235), and a protein containing a deletion at both N- During the course of purification, we noticed that the
and C-termini (IN53-235). The numbers in the nomencla- activities of the deletion mutants were affected by the
ture of the mutant proteins refer to the amino acid resi- presence of the His-tag at the N-terminus. In contrast to
dues of the wild-type integrase that are retained in the
deletion derivatives. A mutant protein, D118N, was also
prepared that contains a single amino acid substitution
in the DD35E motif; the highly conserved aspartic acid
at position 118 was substituted with asparagine. The
mutant integrases were tested for their abilities to medi-
ate 3*-end processing, 3*-end joining, and disintegration
(Table 1). Except for IN1-235, deletion at either N- or C-
terminus, or both termini, rendered the proteins unable
to mediate 3*-end processing and 3*-end joining. The
truncated integrases, however, still retained disintegra-
tion activity. Unlike all other deletion derivatives, IN1-235
had a considerable level of 3*-end processing (35% of
wild type) and a weak 3*-end joining activity (2% of wild
type) (Fig. 4 and Table 1). A full-length protein containing
a single amino acid substitution of the aspartic acid at
position 118 was completely inactive for all three reac-
tions. The results confirmed that the catalytic site is lo-
FIG. 4. Catalytic activities of C-terminal truncated FIV integrase (IN1-cated in the core region of integrase, from amino acid
235). Five nanomolar of the fully double-stranded (F-U5V1/F-U5V2,residues 53 to 188, and confirmed that D118 is one of
lanes 1–3) or preprocessed (F-U5V1/F-U5V2, lanes 4–6) was incubated
the catalytic triad residues conserved in all retroviral in- with the indicated concentrations of IN1-235 under standard reaction
tegrases (Polard and Chandler, 1995). For all the mutant conditions. The symbols have the same connotations as described in
the legend of Fig. 2.derivatives, the activity profile was qualitatively un-
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FIG. 5. In vitro activities of His-tag containing FIV integrase and its deletion derivatives. Five nanomolar of the double-stranded oligonucleotide
(F-U5V1/F-U5V2) was incubated with the indicated concentrations of His-WT (lanes 1–5), WT (lanes 6–10), His-IN53-281 (lanes 11–15), or His-IN1-
235 under standard reaction conditions. The symbols have the same connotations as described in the legend of Fig. 2.
the results described earlier in Table 1, deletion mutants two- to fourfold. The His-tag had no discernable effect
IN53-281 and IN1-235 could efficiently mediate 3*-end on the activity of D118N mutant (Table 2).
processing and 3*-end joining when the His-tag was not The effect of the His-tag on the activity of the wild-type
cleaved from the fusion proteins (Fig. 5, lanes 11–20; integrase was more complex. Retention of the His-tag
Table 2). For IN1-188 and IN53-235, retention of the His- had no effect on 3*-end processing and disintegration
tag did not restore the 3*-end processing and 3*-end but decreased the 3*-end joining activity (Fig. 5, lanes
joining activities but increased the disintegration activity 1–5). More importantly, the presence of the His-tag sig-
nificantly altered the selection of integration sites, as
indicated by a change of the banding patterns of the 3*-
TABLE 2 end joining products. In the presence of the His-tag, there
Catalytic Activitiesa of Mutant FIV Integrases Containing was a preference for integrating near the 3*-ends of the
a His-tag at the N-Terminus target DNA and integration into the rest of the molecule
was infrequent (Fig. 5, lanes 1–5). In the absence of the
Integrase 3*-end 3*-end
His-tag, in addition to the 3* ends, significant amountsderivative processing joining Disintegration
of integration occurred near the 5* ends and the internal
WT //// //// //// region of the target molecule (Fig. 5, lanes 6–10).
His-WT //// /// //// To understand the mechanism by which the His-tag
His-IN53-281 { { //// altered the target site preference of wild-type integrase
His-IN1-235 /// // ///
and changed the activity of deletion mutants, a syntheticHis-IN1-188 0 0 {
12-amino acid peptide corresponding to the His-tag wasHis-IN53-235 0 0 ////
His-D118N 0 0 0 added to an integration reaction containing the wild-type
integrase, or the N-terminus deletion mutant IN53-281,
a Results are expressed as the percentage of the activity of wild-
or the C-terminus deletion mutant IN1-235. In all cases,type FIV integrase (WT). Reactions were conducted in the presence
the addition of the synthetic His-tag, in a molar ratioof 30 mM NaCl. Other reaction conditions and symbols are as in
Table 1. ranging from 1 to 20, did not change the activity nor the
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TABLE 3 integrase was relaxed and the protein was active on
oligonucleotides containing sequences derived from theEffect of His-Tag on the Dissociation Constant of FIV Integrase
U5 end of HIV-1 and MLV.and Its Mutant Derivativesa
Analysis of the deletion and substitution mutants
Kdb (nM) showed that although full-length integrase is required for
efficient 3*-end processing and 3*-end joining, the central
Integrase derivative 0His /His
core domain itself (residues 53–188) is sufficient for dis-
integration, and thus contains the catalytic site. Comple-WT 16 2
IN53-281 550 2 mentation experiments using various mutants showed
IN1-235c 340 4 that FIV integrase is active as a multimer, and that differ-
D118N 1 NDd ent functions can be provided by discrete domains on
different subunits. The catalytic activities of HIV-1 inte-a Reactions were conducted in the presence of standard reaction
grase (Engelman et al., 1993; van Gent et al., 1993), RSVbuffer containing 17.5 mM NaCl. The substrate was a double-strand
oligonucleotide (F-U5V1/F-U5V2). integrase (Jones et al., 1992), MLV integrase (Jonsson et
b The dissociation constant was calculated from the slope of a al., 1996), HFV integrase (Pahl and Flugel, 1995), and Mu
Scatchard plot (Munson, 1983) using the equation [LR]/[L]  ([LR]max transposase (Baker et al., 1994) also involve multimeriza-0 [LR])/Kd. [L], concentration of free DNA substrate; [LR], concentration
tion of protein subunits, suggesting that formation of anof DNA bound to integrase; [LR]max , maximum amount of DNA bound.
active multimer is a general feature of proteins in thec In the presence of 10 mM NaCl, the Kd of the nontagged (0His) IN
1-235 was 250 nM. integrase/transposase family.
d ND, not determined. A C-terminal truncated mutant of FIV integrase, IN1-
235, displayed an activity profile not seen previously in
studies of other integrases. The levels of 3*-end pro-
distribution of integration (data not shown). The result
cessing and disintegration were 35 and 50%, respec-
suggested that the His-tag cannot be provided in trans for
tively, of wild-type integrase. The 3*-end joining activity,
the observable effects and is required in cis to integrase.
however, was very weak (2% of wild type). The result
One possible means by which the His-tag exerted its
indicates that the C-terminus of FIV integrase is not
effect could be by altering the binding affinity of the pro-
strictly required for catalysis nor recognition and binding
tein to DNA. The hypothesis was tested by determining
of the LTR substrate. The inefficiency of IN1-235 to medi-
the dissociation constant (Kd) of wild-type and various ate 3*-end joining suggests that the C-terminus is primar-
mutant derivatives with or without the His-tag at the N-
ily involved in interacting with target DNA. Based on its
terminus, using FIV U5 DNA (Table 3). In the absence of
ability to bind DNA nonspecifically, the C-terminus of
the His-tag, the Kd of the wild-type integrase was 16 nM, HIV-1 integrase (residues 213–288) is postulated to be
whereas the Kd of the deletion mutants IN53-281 and the target DNA-binding domain (Woerner et al., 1992;
IN1-235 were 550 and 340 nM, respectively. The high Kd Vink et al., 1993; Engelman et al., 1994; Puras Lutzke et
of the deletion mutants could be related to their poor 3*-
al., 1994). However, no C-terminal deletion derivatives of
end processing and 3*-end joining activities. The Kd of HIV-1 integrase have been reported to efficiently mediate
the catalytically inactive D118N mutant was lower than
3*-end processing. Interestingly, the N-terminal deletion
that of the wild type, indicating that the defect was not
derivative of RSV integrase (RSV IN54-286) behaves simi-
due to inefficient binding to DNA. For all proteins tested,
larly to FIV IN1-235. It can mediate 3*-end processing
retention of the His-tag decreased the Kd values to 2– 4 and disintegration, and possesses a very weak joining
nM. The change observed with wild-type integrase was
activity. The C-terminus of RSV integrase, however, is at
moderate. The change observed with the deletion mu-
least required for 3*-end joining (Bushman and Wang,
tants, however, represented a 85- to 275-fold increase in
1994). It seems, therefore, among the retroviral integ-
DNA binding affinity, which might explain their enhanced
rases, there are differences in domain organization and
enzymatic activities.
function that contribute to different domain requirements
for activity. Alternatively, the domain requirement for in-
DISCUSSION
tegrase activity may be masked in certain deletion mu-
tants as a result of the reaction condition in vitro.We expressed FIV integrase and its mutant derivatives
in E. coli and characterized the in vitro activities of the Attachment of a His-tag at the N-terminus of deletion
derivatives of FIV integrase had a significant effect onpurified products. Like integrase of HIV-1 and other re-
troviruses (for reviews, see Vink and Plasterk, 1993; Katz the activities. Notably, the weak 3*-end joining activity of
IN1-235 and the absence of 3*-end processing and join-and Skalka, 1994), the wild-type FIV integrase possesses
3*-end processing, 3*-end joining, and disintegration ac- ing activities of IN53-281 were restored by the presence
of the His-tag. A similar stimulation of activity by a His-tivities. All three activities of FIV integrase were abso-
lutely dependent on the presence of a divalent cation, tag is also observed with deletion derivatives of HIV-1
and RSV integrases (Bushman and Wang, 1994; Hickmaneither Mn2/ or Mg2/. The substrate specificity of FIV
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et al., 1994). Since the stimulation could not be repro- and the effect of integrase inhibitors on retrovirus infec-
tion.duced by the addition of a synthetic His-tag peptide, it
appears that the His-tag acts in cis to integrase. We
found that, by having the His-tag at the N-terminus, the
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